Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, marks a significant expansion of their joint product pipeline and reinforces their international collaboration in genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It plays a critical role in the processing of vitamins, neurotransmitters, and other biological molecules, influencing overall health. While standard tests analyze only a limited set of genes, MGT Plus covers 27 genes, offering a more comprehensive view of methylation across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, vascular health, immune function, and cellular health. This broader scope allows for more precise insights into key biochemical processes, enabling more personalized prevention and health strategies.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of the new test: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally."
The launch comes at a time when the global direct-to-consumer testing market is experiencing robust growth. In 2025, the market was valued at approximately $4.7 billion and is projected to reach over $16.0 billion by 2033. The genetic testing segment is particularly dynamic, accounting for over 40% of the market, with North America leading at around 50% of global volume in 2025. This growth is driven by increasing consumer interest in personalized health information and preventive care.
Novogenia AG, headquartered in Munich, Germany, is a European healthcare company active in human genetics and the development of personalized products based on genetic analysis. Their laboratory conducts genetic analyses used in diagnosis, treatment, and prevention, as well as in the production of tailored nutritional supplements and cosmetics. The company partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize patient care based on genetic predispositions. Novogenia also invests in innovative biotech, healthcare, and life sciences companies. More information is available at Novogenia's website.
